Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAPHNe: De-escalation to Adjuvant Antibodies Post-pCR to Neoadjuvant THP in HER2-positive Breast Cancer
NCT03716180Phase 1Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Nov 2018
- Primary completion
- Oct 2020
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Paclitaxel Micelles for Injection, trastuzumab and pertuzumab in breast cancer, sponsored by Dana-Farber Cancer Institute. Primary endpoint: Adjuvant chemotherapy Received at 2.5 years. Started Nov 2018; status: active, not recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03716180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03716180.